Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

40.11
-1.3350-3.22%
Pre-market: 40.310.2003+0.50%08:17 EDT
Volume:3.25M
Turnover:130.30M
Market Cap:6.73B
PE:103.31
High:41.26
Open:41.10
Low:39.11
Close:41.45
52wk High:55.67
52wk Low:27.00
Shares:167.76M
Float Shares:155.00M
Volume Ratio:1.41
T/O Rate:2.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:3.72
PE(LYR):28.05

Loading ...

Alkermes Plc : Leerink Partners Cuts Target Price to $45 from $50

THOMSON REUTERS
·
Yesterday

Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study

TIPRANKS
·
Yesterday

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02

Reuters
·
Oct 03

Alkermes (ALKS), What Is Behind The Fresh Attention?

Simply Wall St.
·
Oct 02

Alkermes (ALKS) Gets a Hold from Goldman Sachs

TIPRANKS
·
Sep 24

Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says

MT Newswires Live
·
Sep 22

Analysts’ Opinions Are Mixed on These Healthcare Stocks: AnaptysBio (ANAB), Alkermes (ALKS) and Iradimed (IRMD)

TIPRANKS
·
Sep 22

Alkermes Plc : Jefferies Raises Target Price to $83 from $78

THOMSON REUTERS
·
Sep 22

Alkermes data show measurable improvements in ADHD, says H.C. Wainwright

TIPRANKS
·
Sep 22

Alkermes Price Target Maintained with a $62.00/Share by Needham

Dow Jones
·
Sep 21

Alkermes Plc : Baird Raises Target Price to $61 from $58

THOMSON REUTERS
·
Sep 21

Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell

MT Newswires Live
·
Sep 21

U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes

Reuters
·
Sep 21

Alkermes jumps 8% to $46.99 after Phase I adult ADHD data

TIPRANKS
·
Sep 21

S&P 500 Futures Rise in Premarket Trading; Ingram Micro, Kite Realty Group Trust Lag

Dow Jones
·
Sep 21

Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug

THOMSON REUTERS
·
Sep 21

Alkermes announces Phase 1b results of ALKS 7290 in ADHD

TIPRANKS
·
Sep 21

Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD

Reuters
·
Sep 21

Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd

THOMSON REUTERS
·
Sep 21

Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)

THOMSON REUTERS
·
Sep 21